Skip to main content

Generic Lexapro Approved for Adult Depression, Anxiety


March 14, 2012 — The US Food and Drug Administration (FDA) today approved escitalopram tablets for the treatment of adults with depression and general anxiety disorder, making this the first generic version of Lexapro (Forest Pharmaceuticals) to receive FDA approval for treating both disorders.
"These psychiatric conditions can be disabling and prevent a person from doing everyday activities," Janet Woodcock, MD, director of the FDA's Center for Drug Evaluation and Research, said in a release.
"This medication is widely used by people who must manage their condition over time, so it is important to have affordable treatment options," added Dr. Woodcock.
Today's approval will allow Teva Pharmaceutical Industries/IVAX Pharmaceuticals to market the generic tablets in dosages of 5, 10, and 20 mg. In addition, the FDA granted a 180-day period of generic drug exclusivity to Teva.
The most common treatment-related adverse effects reported in past studies that evaluated this medication have included insomnia, decreased libido, ejaculation disorder, excessive sweating, fatigue, nausea, and drowsiness.
As with other antidepressants, escitalopram comes with a boxed warning and patient medication guide calling for careful monitoring during the start of use and reporting that there is an increased risk for suicidal ideation in those younger than 24 years.
However, the warning also notes that this risk has not been found in those older than 24 years and that those older than 64 years have actually seen a decrease in these behaviors.

Comments

Post a Comment

Popular posts from this blog

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

CareFusion Issues Update on Infant Breathing Product Recall

July 5, 2012 — Medical device maker CareFusion has issued an update reminding healthcare providers of its voluntary recall of its Air Life ™ Infant Breathing Circuit, initiated back in May. The US Food and Drug Administration (FDA) has classified this action as a class 1 recall, meaning there is a reasonable probability of serious adverse health consequences or death associated with use of the defective units. The update was posted July 2 on the FDA  Website. On May 29, 2012, CareFusion sent an  Urgent Recall Notice  to customers and distributors stating that the company had identified potential risks associated with the Air Life  Infant Breathing Circuit. The action was initiated after the company received complaints of the Y adapter within the breathing circuit developing cracks during patient use. "If a crack develops in the Y adapter, this could potentially result in a leak in the closed ventilation system, leading to a loss in the intended tidal volum...
Post a Comment
Read more

FDA Approvals: Pazopanib for Advanced Soft Tissue Sarcoma

CLINICAL CONTEXT Pazopanib was first approved by the US Food and Drug Administration (FDA) in 2009 when it became the sixth drug approved to treat advanced renal cell carcinoma. It is a small molecule with a mechanism of action as a tyrosine kinase inhibitor, specifically targeting receptors involved in angiogenesis and tumor cell proliferation. These include vascular endothelial growth-factor receptors 1, 2, and 3; platelet-derived growth-factor receptors α and β; fibroblast growth-factor receptors 1 and 3; stem cell factor receptors; interleukin-2-inducible T-cell kinase; leukocyte-specific protein tyrosine kinase; and transmembrane glycoprotein-receptor tyrosine kinase. STUDY SYNOPSIS AND PERSPECTIVE The FDA has approved pazopanib ( Votrient ) for the treatment of advanced soft tissue sarcoma in patients who have received previous chemotherapy. Pazopanib is already marketed for the treatment of advanced renal cell carcinoma; when it was approved in 2009, it became the six...
Post a Comment
Read more